The use of immune checkpoint inhibitors (ICIs) continues to transform the therapeutic
landscape of non-small cell lung cancer (NSCLC), with these drugs now being evaluated at …

Background Prognostic nutritional index (PNI) has been identified as a reliable prognostic
factor for cancer adjuvant therapy. However, its prognostic value in lung cancer patients …

Dynamic changes in the blood-based biomarkers could be used as a prognostic biomarker
in patients treated with immune checkpoint inhibitors (ICIs), although the data are limited …

Simple Summary Despite the promising results not all patients with advanced non-small cell
lung cancer benefit from immunotherapy. Immunotherapy may cause severe adverse …

Background Treatment-related lymphopenia (TRL) is common in patients with lung cancer,
particularly in those with radiotherapy. However, the influence of TRL on the efficacy of …

Introduction The spleen is a lymphoid organ and we hypothesize that clinical benefit to
immunotherapy may present with an increase in splenic volume during treatment. The …

Immune checkpoint inhibitors (ICIs) improve outcomes in advanced melanoma, but many
patients are refractory or experience relapse. The gut microbiota modulates antitumor …

Abstract Purpose Immune checkpoint inhibitors (ICIs) dramatically changed the prognosis of
patients with NSCLC. Unfortunately, a reliable predictive biomarker is still missing …

Background The Prognostic Nutritional Index (PNI) has become an important predictive tool
for assessing patients' nutritional status and immune competence. It is widely used in …

We present a study where predictive mechanistic modeling is combined with deep learning
methods to predict individual patient survival probabilities under immune checkpoint …